Tag: farnesene

Amyris inks 5-year $100M+ biofene supply pact for nutraceutical market

Amyris inks 5-year $100M+ biofene supply pact for nutraceutical market

April 28, 2016 |

In California, the Eco-Emirs of Emeryville, Amyris executed a five year Biofene supply agreement with a global nutraceuticals company. Upping the ante from January This new, long-term agreement replaces the parties’ one-year purchase agreement, which was previously announced on January 4, 2016.  More on that deal here. Under the new supply agreement, the mystery customer […]

Read More

First-ever commercial flight on farnesene flies Orlando to Sao Paolo

First-ever commercial flight on farnesene flies Orlando to Sao Paolo

July 31, 2014 |

In Florida, GOL’s flight 7725 that departed from Orlando, Florida on July 30 at 5:15 PM ET and traveled to Sao Paulo, Brazil, was the industry’s first commercial flight with farnesane. GOL committed to fly its Boeing 737 fleet with up to a 10 percent blend of the renewable farnesane fuel starting with this initial […]

Read More

Intrexon makes farnesene from methane: hot route to low-cost jet fuels and diesels?

Intrexon makes farnesene from methane: hot route to low-cost jet fuels and diesels?

July 1, 2014 |

Second Product of Intrexon’s Proprietary Bioconversion Platform Following Isobutanol Who’s happy, who’s bumming — and how far along is the work, really? The Digest looks at Intrexon’s breakthrough. Gas-to-Liquids approach significantly more cost-efficient versus conventional methods, company says. In California, Intrexon announced the bioconversion of methane to farnesene in the lab with its proprietary platform. Farnesene […]

Read More

Spring blossoms: Amyris swings to positive earnings for Q1 2014, affirms guidance

Spring blossoms: Amyris swings to positive earnings for Q1 2014, affirms guidance

May 11, 2014 |

In California, Amyris announced net income of $16.4M on revenues of $6.2M for Q1 2014, after reporting a $32.6M loss in Q1 2013 on revenues of $9.0M. The change in net income was primary due to a non-cash benefit relating to outstanding convertible notes, a result of a decrease in the Company’s stock price at […]

Read More

Amyris hits the comeback trail

Amyris hits the comeback trail

December 28, 2012 |

Biofene production starts up in Paraiso, Brazil – sales expected to commence in Q1 2013 – Total, Temasek, Biolding inject fresh capital. What’s next for biofuels’ “Comeback Kid”? By now, most of the “smart set” that found itself excited about Amyris, and about advanced synthetic biofuels during the IPO fever, have moved on. They read […]

Read More

Don't Smoke That Fuel: ARPA-E funds energy research in tobacco, turpentines, camelina

Don't Smoke That Fuel: ARPA-E funds energy research in tobacco, turpentines, camelina

October 14, 2011 |

Transformative yields for terrestrial plant oils of up to 4,000 gallons per acre are the goal of new research awards from ARPA-E. In Washington, the Department of Energy’s Advanced Research Projects Agency-Energy (ARPA-E), today announced 60 cutting-edge research projects aimed at dramatically improving how the U.S. produces and uses energy.  10 awards for $36 million […]

Read More

Amyris opens first commercial facility

Amyris opens first commercial facility

[ 0 ] April 29, 2011 |

In California, Amyris announced the completion of the first industrial-scale production facility, in Piracicaba, São Paulo, Brazil at a facility owned by Biomin do Brasil Nutriҫão Animal Ltda., a company focusing on animal nutrition. The production facility is located expects to begin Biofene production in May. Amyris feeds sugar cane syrup into three dedicated 200,000 […]

Read More

Amyris upgraded to Outperform; farnesene production, offtake, scale are key

Amyris upgraded to Outperform; farnesene production, offtake, scale are key

[ 0 ] April 6, 2011 |

In California, Raymond James analyst Pavel Molchanov upraded Amyris’ stock from Market Perform to Outperform with a share price target of $31, commenting that “With shares down 13% since March 24, erasing virtually all of the year-to-date gains, we believe the risk/reward profile has become more attractive.” Molchanov wrote that “this won’t be an earnings […]

Read More